GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Equity-to-Asset

ZYUS Life Sciences (TSXV:ZYUS) Equity-to-Asset : 0.56 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ZYUS Life Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$23.11 Mil. ZYUS Life Sciences's Total Assets for the quarter that ended in Dec. 2023 was C$41.63 Mil. Therefore, ZYUS Life Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.56.

The historical rank and industry rank for ZYUS Life Sciences's Equity-to-Asset or its related term are showing as below:

TSXV:ZYUS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07   Med: 0.31   Max: 0.56
Current: 0.56

During the past 3 years, the highest Equity to Asset Ratio of ZYUS Life Sciences was 0.56. The lowest was 0.07. And the median was 0.31.

TSXV:ZYUS's Equity-to-Asset is ranked worse than
52.39% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs TSXV:ZYUS: 0.56

ZYUS Life Sciences Equity-to-Asset Historical Data

The historical data trend for ZYUS Life Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences Equity-to-Asset Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Equity-to-Asset
- 0.07 0.56

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only 0.07 - 0.63 0.65 0.56

Competitive Comparison of ZYUS Life Sciences's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Equity-to-Asset falls into.



ZYUS Life Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

ZYUS Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=23.114/41.627
=0.56

ZYUS Life Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=23.114/41.627
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZYUS Life Sciences  (TSXV:ZYUS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


ZYUS Life Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ZYUS Life Sciences (TSXV:ZYUS) Business Description

Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines